Slides
Page 1
Investor Relations 28 October 2025 Earnings Release 2025 Q3
Page 3
• Signed USD 1.3B CMO contract with a U.S.pharma - Q3 cumulative orders approached last year’s full-year total • Cumulative CMO orders exceeded USD 20B since inception • 8 new CDO contract wins, including with global pharma • Cumulative orders: USD20.1B, CMO 105, CDO 154 • SB17 (bStelara): Completed the U.S. launches of private label product • SB16 (bProlia, bXgeva) : Launched in Korea • SB11 (bLucentis), SB15 (bEylea) : Partnership with Harrow for commercialization in the U.S. • Rev. +40%, OP+115% on expanded operations at Plant 4 - Consolidated: Rev.1,660B, OP729B(OPM: 43.9%) - Biologics: Rev.1,258B, OP633B(OPM: 50.4%) - Bioepis: Rev.KRW 441B, OP 129B(OPM: 29.3%) • On-track to meet full-year guidance with Plant 4 ramp-up • Smooth progressof equity spin-off between SBL & SEH - Key regulatory approvals completed - Resolution passed at Extraordinary General Meeting • Contracts signed with 4 of Japan’s top 10 pharma companies; 1 under final negotiation
Page 4
1,034 1,187 1,660 319 (30.8%) 339 (28.5%) 729 (43.9%) 2023 2024 2025 +40% +29% +115% Revenue Operating Profit 2,621 3,291 4,248 764 (29.1%) 994 (30.2%) 1,691 (39.8%) 2023 2024 2025 +70% 457 (44.2%) 495 (41.7%) 908 (54.7%) 1,112 (42.4%) 1,443 (43.8%) 2,212 (52.1%) Revenue Operating Profit
Page 6
2,111 2,547 3,271 871 (39.8%) 1,007 (38.0%) 1,541 (47.1%) 2023 2024 2025 883 1,067 1,258 382 (43.3%) 445 (41.7%) 633 (50.4%) 2023 2024 2025 +28% +53% 451 (51.1%) 527 (49.3%) 729 (58.0%) 1,056 (50.0%) 1,234 (48.4%) 1,815 (55.5%) Revenue Operating Profit Revenue Operating Profit
Page 7
14 16 23 29 40 4715 19 25 31 36 4563 104 164 219 270 302 CMO Contract Amount* # of CMO Projects (DS/DP) # of CDO Projects (Unit: USD B) 56 69 74 88 99 105 63 87 101 112 133 154
Page 9
731 1,140 1,243 127 (17.4%) 363 (31.8%) 347 (27.9%) 2023 2024 2025 262 330 441 49 (18.8%) 68 (20.6%) 129 (29.3%) 2023 2024 2025 +9% 63 (23.9%) 83 (25.0%) 147 (33.3%) 164 (22.4%) 408 (35.8%) 399 (32.1%) Revenue Operating Profit Revenue Operating Profit
Page 10
Soliris® (Eculizumab) Samsung Bioepis ('23) Teva ('25) ® (Etanercept) Remicade® (Infliximab) Humira® (Adalimumab) Stelara® (Ustekinumab) Biogen ('16) Biogen ('16) Biogen ('18) Sandoz ('24) - Organon ('17) Organon ('23) Sandoz ('25) Cordavis, Quallent Herceptin® (Trastuzumab) Avastin® (Bevacizumab) Keytruda® (Pembrolizumab) Organon ('18) Organon ('20) - Organon ('20) - Lucentis® (Ranibizumab) Eylea® (Aflibercept) Biogen ('23) Biogen → Harrow ('22) Prolia® / Xgeva® (Denosumab) -
Page 12
May 22 • BOD Resolution and Spin-off Announcement Completed Jul. 29 • Record Date for EGM Oct. 2 • Notice of EGM Oct. 17 • Notice of Share Consolidation • EGM for Spin-off Approval Oct. 30 • Commencement of Trading Suspension (~ Nov.21) Scheduled Oct. 31 • Record Date for New Share Allocation Nov. 1 • Completion of the Spin-off Process Nov. 24 • Share trading resumes for both entities SBL SEH
Page 13
Expanding biosimilar portfolio Driving growth through a stable/improving revenue and margin Advancing novel pipelines Execute strategic investments and operational excellence Maximizing group-wide business synergies Securing future growth drivers through M&A and Licensing-In Lean/agile biotech model Developing peptide platform technologies with differentiated/enhanced capabilities Designing dual-antibody structures for ADC applications
Page 15
AchievingGlobal Leadership in Carbon Neutrality Approved enhancedSMI carbon neutrality targets Engaging bio/pharma SMI members and supply chain partners to align and achieve shared goals Enhancement of ESG Management System (Environmental) Establishedcarbon footprint measurement system · Calculating product-level emissions to achieve carbon neutrality (Social) Set supply chain carbon neutrality targets and provided support · Conducted consulting for 5 domestic partners (Governance) Completed ethicsmanagement assessmentframework · Established global management indicators and annual evaluation process Category New Carbon Neutrality Targets GHG Emissions Calculate and disclose Scope 1∼3 emissions (∼'25) Disclose PCF of top 10 high-emission products (∼'28) Establish and disclose SBTi-verified reduction targets (∼'27) Renewable Energy Achieve at least 80% transition to renewal energy (∼'30) Thermal Emissions Reduce process heat emissions by at least 20% (∼'30) Resource Efficiency Improve waste reduction and recycling rates; procure low-carbon materials; set and disclose reduction targets for chemical-related emissions Natural Capital & Water Conduct impact assessment on natural capital (∼'28) Set water reuse targets and monitor pollutants (∼'30) Supplier Management Integrate SMI carbon neutrality targets into supplier selection process Climate ReportingAligned with IFRS-S2 Developing strategies, governance, and metrics in alignment with IFRS-S2 Establishing a phased approach to identify and mitigate climate risks and opportunities: Identification → Business impactassessment → Response strategy→ Financialimpact and resilience analysis
Page 17
1,067 330 1,187 521 198 544 77 130 205 445 68 339 424 41 291 323 40 264 527 83 495 49.3% 25.0% 41.7% 1,258 441 1,660 736 283 979 103 154 250 633 129 729 663 138 767 496 122 575 729 147 908 58.0% 33.3% 54.7% +473 (+39.9%) +435 +45 +390 (+115.2%) +476 +310 +412 (+83.2%)
Page 18
16,046 17,336 5,522 5,518 2,018 1,299 10,524 11,818 6,216 6,432 4,158 3,853 2,058 2,578 1,628 1,340 9,830 10,905 178 178 5,663 5,663 4,003 5,087 (14) (23)
Page 19
Thank You